Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products.
T cell modification
TCR-T cells manufacturing
academia
clinical scale
pipeline
process development
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
03
2022
accepted:
13
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
Cellular immunotherapies based on T cell receptor (TCR) transfer are promising approaches for the treatment of cancer and chronic viral infections. The discovery of novel receptors is expanding considerably; however, the clinical development of TCR-T cell therapies still lags. Here we provide a pipeline for process development and clinical-scale manufacturing of TCR-T cells in academia. We utilized two TCRs specific for hepatitis C virus (HCV) as models because of their marked differences in avidity and functional profile in TCR-redirected cells. With our clinical-scale pipeline, we reproduced the functional profile associated with each TCR. Moreover, the two TCR-T cell products demonstrated similar yield, purity, transduction efficiency as well as phenotype. The TCR-T cell products had a highly reproducible yield of over 1.4 × 10
Identifiants
pubmed: 35784320
doi: 10.3389/fimmu.2022.896242
pmc: PMC9243500
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
896242Informations de copyright
Copyright © 2022 Silva, Chrobok, Rovesti, Healy, Wagner, Maravelia, Gatto, Mazza, Mazzotti, Lohmann, Sällberg Chen, Sällberg, Buggert and Pasetto.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Exp Med. 2003 Jun 16;197(12):1645-55
pubmed: 12810686
Immunol Rev. 2019 Jul;290(1):127-147
pubmed: 31355495
Hepatology. 2001 Jan;33(1):267-76
pubmed: 11124845
Hum Gene Ther Methods. 2016 Dec;27(6):209-218
pubmed: 27897048
Cancer Immunol Immunother. 2007 May;56(5):739-45
pubmed: 17195077
J Immunother. 2008 Nov-Dec;31(9):830-9
pubmed: 18833004
J Biomol Screen. 2006 Dec;11(8):922-32
pubmed: 16973921
Front Immunol. 2019 Oct 10;10:2361
pubmed: 31649672
Cancer Immunol Immunother. 2013 Oct;62(10):1563-73
pubmed: 23903715
Nat Med. 2020 Oct;26(10):1569-1575
pubmed: 33020647
Leukemia. 2017 Dec;31(12):2587-2593
pubmed: 28490811
J Gen Virol. 2012 Feb;93(Pt 2):247-258
pubmed: 22071510
J Virol. 2007 Aug;81(16):8468-76
pubmed: 17553885
Gene Ther. 2021 Sep;28(9):572-587
pubmed: 33867524
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Front Oncol. 2021 Sep 17;11:723888
pubmed: 34604060
Immunity. 2020 Nov 17;53(5):985-1000.e11
pubmed: 33128876
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Mol Ther Methods Clin Dev. 2020 Dec 25;20:379-388
pubmed: 33575430
Blood Cancer Discov. 2021 Sep;2(5):408-422
pubmed: 34568831
Front Immunol. 2020 Mar 20;11:482
pubmed: 32528460
PLoS One. 2013 Oct 21;8(10):e77106
pubmed: 24204746
Viruses. 2018 Oct 06;10(10):
pubmed: 30301201
Nat Microbiol. 2021 Feb;6(2):187-195
pubmed: 33257849
Br J Cancer. 2021 May;124(11):1759-1776
pubmed: 33782566
Drug Des Devel Ther. 2018 Oct 05;12:3343-3356
pubmed: 30323566
Mol Ther Methods Clin Dev. 2014 May 14;1:14015
pubmed: 26015959
J Virol. 2007 Nov;81(21):12071-6
pubmed: 17728221
Immunogenetics. 1985;21(3):235-46
pubmed: 3872841
J Hematol Oncol. 2021 Jun 30;14(1):102
pubmed: 34193217
Gastroenterology. 2009 Apr;136(4):1391-401
pubmed: 19185579
Nature. 2021 Sep;597(7877):544-548
pubmed: 34526724
Cell Death Dis. 2017 May 4;8(5):e2758
pubmed: 28471451
J Virol. 2017 Apr 13;91(9):
pubmed: 28228595
Cancer Res. 2006 Sep 1;66(17):8878-86
pubmed: 16951205
Front Immunol. 2018 May 30;9:1062
pubmed: 29899740
PLoS One. 2015 Jun 01;10(6):e0128151
pubmed: 26030772
Hum Gene Ther. 2016 Oct;27(10):860-869
pubmed: 27562135
Sci Immunol. 2020 Nov 6;5(53):
pubmed: 33158974
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
J Immunol. 2012 Nov 1;189(9):4510-9
pubmed: 23024278
Cancer Chemother Pharmacol. 2000;46 Suppl:S52-61
pubmed: 10950149
Hepatol Int. 2021 Dec;15(6):1402-1412
pubmed: 34850325
Mol Ther Oncolytics. 2016 Jun 15;3:16015
pubmed: 27347557
Eur J Immunol. 2008 Oct;38(10):2665-77
pubmed: 18958874
Sci Rep. 2021 Jan 11;11(1):389
pubmed: 33431989
Cell Rep. 2016 Nov 8;17(7):1773-1782
pubmed: 27829149
Cancer Immunol Immunother. 2014 Oct;63(10):999-1008
pubmed: 24938475
J Infect Dis. 2021 Jan 4;223(1):128-138
pubmed: 31994701
J Immunother. 2009 Feb-Mar;32(2):169-80
pubmed: 19238016
Hum Gene Ther. 2017 Oct;28(10):914-925
pubmed: 28847167
J Virol. 2008 Oct;82(20):10017-31
pubmed: 18667516
J Exp Med. 2000 May 1;191(9):1499-512
pubmed: 10790425
Cancer Res. 2011 May 15;71(10):3516-27
pubmed: 21558388
J Clin Oncol. 2020 Jun 10;38(17):1938-1950
pubmed: 32286905
Blood. 2021 Apr 29;137(17):2321-2325
pubmed: 33512414
Methods Mol Biol. 2009;510:145-63
pubmed: 19009259
Cancers (Basel). 2019 Jan 10;11(1):
pubmed: 30634595
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426437
Adv Ther (Weinh). 2021 Aug;4(8):
pubmed: 34541300
Cytotherapy. 2016 Aug;18(8):1002-1011
pubmed: 27378344
Front Immunol. 2020 Aug 07;11:1941
pubmed: 32849651